A Mayo Clinic study published in the New England Journal of Medicine demonstrates that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most aggressive and treatment-resistant forms of the disease.Â
Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free survival compared to lomustine alone in patients with recurrent IDH mutant, grade 3 astrocytoma.Â
Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver cancer risk for those with hepatitis C.
Researchers at the LSU LCMC Health Cancer Center examined tumors from more than 250 Black and white women across Louisiana and uncovered key immune differences in patients with triple-negative breast cancer, one of the most aggressive forms of breast cancer.
Researchers have discovered a previously unknown pathway that could explain why androgens remain and prostate cancer progresses despite treatment with androgen deprivation therapy.
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those that typically escape detection, with fewer toxic side effects.Â
Researchers at UT Southwestern Medical Center have identified a protein that causes human cell membranes to break open in a form of inflammatory programmed cell death called necroptosis.Â
A clinical guideline from the American Society for Radiation Oncology is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration with systemic therapy, and treatment delivery.Â
For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.Â
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia is driving better survival and cure rates.Â
